Loading patent…
AssigneeAgency for Science, Technology and Research
InventorsMei Yee Vanessa Ding, Boon Hwa Andre Choo, Wey Jia Fong
Estimating the term…
The present invention relates to antigen-binding proteins, or antigen-binding fragments thereof that bind to a glycan on the AXL receptor tyrosine kinase. The present invention also relates to antigen-binding proteins, or antigen-binding fragment conjugated to a radioisotope or cytotoxin, and wherein said antigen-binding proteins, or antigen-binding fragment is internalised into a cell upon binding to AXL receptor tyrosine kinase. Compositions comprising a physiologically acceptable carrier and a therapeutically effective amount of the antigen-binding protein, or antigen-binding fragment thereof, therapeutic use of the antigen-binding protein, or antigen-binding fragment thereof, methods for detecting cancer as well as kits when used in such methods are also provided.
An antigen-binding protein, or an antigen-binding fragment thereof, that binds to AXL receptor tyrosine kinase, comprising (i) a heavy chain variable domain (VH) comprising a VH complementarity determining region (CDR) 1 (VHCDR1) having the amino acid sequence GFTFTSYYMY (SEQ ID NO:
An antibody that comprises a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO:
A method of treating an AXL-expressing cancer comprising administering an antigen-binding protein, or an antigen-binding fragment thereof, that binds to AXL receptor tyrosine kinase, to a subject in need thereof, wherein the antigen-binding protein, or the antigen-binding fragment thereof, comprises (i) a heavy chain variable domain (VH) comprising a VH complementarity determining region (CDR) 1 (VHCDR1) having the amino acid sequence GFTFTSYYMY (SEQ ID NO:
Dependencies are inferred from the claim text.